Artificial Intelligence for risk classification of AMBLor in the melanoma microenvironment
Presented at the Society for Melanoma Research (SMR) Congress 2021 by Tom Andrew MBChB, MSC, of Newcastle University
AMBLor® will fit very well into pathology workflows as it is a simple dual antibody stain that can be applied to AJCC diagnostic staging biopsies following excision of an early-stage cutaneous melanoma.
Despite rigorous protocols and robust training, subjectivity in real world situations is a risk. In addition pathology units are becoming ever more digitalised. Optimising use of AMBLor for future use is of significant research interest to AMLo.
Here Mr Andrew has demonstrated in a pilot cohort of AJCC stage I/II melanomas that Visiopharm image analysis software identified the presence of AMBRA1 and loricrin to correlate well with current binary histopathology scoring systems.
Click here to read more about the AMBLor test. Click the link below to download the PDF poster.
2021/AMBLor/UK/0024
November 2021
